Related Experiment Videos
Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia
Z A Arlin1, E J Feldman, A Mittelman
1Division of Neoplastic Diseases, New York Medical College, Valhalla 10595.
Insights
Amsacrine effectively treats acute leukemia in patients with cardiac disease, showing significant remission rates. The drug is safe, even for those with arrhythmias, when potassium levels are monitored.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
Background:
- Acute leukemia patients often have co-existing cardiac conditions.
- Reduced left ventricular ejection fraction (LVEF) poses a challenge for standard chemotherapy.
- Amsacrine's efficacy and safety in this specific patient group require evaluation.
Purpose of the Study:
- To assess the efficacy of amsacrine in inducing remission in acute leukemia patients with cardiac disease.
- To evaluate the safety profile of amsacrine in this vulnerable patient population.
- To investigate potential drug-induced cardiotoxicity.
Main Methods:
- Retrospective analysis of 24 patients with relapsed acute leukemia and reduced LVEF treated with amsacrine.
- Inclusion of patients with newly diagnosed acute leukemia and reduced LVEF.
- Endomyocardial biopsies in nine patients to assess cardiac morphology.
- Monitoring of patients with pre-existing arrhythmias and serum potassium levels.
Main Results:
- Nine of 24 patients (37.5%) with relapsed leukemia achieved complete remission (7 AML, 2 ALL).
- Four of six newly diagnosed patients with reduced LVEF also responded to amsacrine.
- No significant drug-induced heart failure was observed on endomyocardial biopsy.
- Amsacrine was safely administered to patients with arrhythmias if serum potassium > 4.0 mEq/l.
Conclusions:
- Amsacrine is a safe and effective therapeutic option for inducing remission in acute leukemia patients with cardiac disease.
- Careful monitoring of potassium levels is crucial for patients with arrhythmias receiving amsacrine.
- Amsacrine does not appear to cause significant cardiotoxicity in this patient cohort.
Abstract:
The role of amsacrine in inducing remission in patients with cardiac disease and acute leukemia was evaluated. There were 17 patients with acute myelogenous leukemia (AML), six with acute lymphocytic leukemia (ALL), and one with biphenotypic leukemia. In this series of 24 patients whose disease had relapsed and who had reduced left ventricular ejection fraction, nine had a complete remission, seven with AML and two with ALL. In addition, four of six with newly diagnosed acute leukemia and reduced left ventricular ejection fraction also responded. Among nine patients who underwent endomyocardial biopsy, none had morphologic changes of sufficient degree to account for drug-induced heart failure. Patients with preexisting arrhythmias received amsacrine without incident if their serum potassium level was higher than 4.0 mEq/l at the time of drug administration. Amsacrine is safe and effective therapy for patients with acute leukemia and cardiac disease.